The Rockefeller University Hospital, a GCRC awardee since 1963, has been the continuous """"""""home"""""""" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of. distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, will integrate and expand their scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new Center will transform clinical and translational research by encouraging new studies, and by enhancing and centralizing the support structures required to conduct studies with scientific rigor and an absolute commitment to protection of human subjects and participant safety. The key elements in the transformation will be: 1) A new governance structure reflecting the NIH cooperative agreement (U54) """"""""assistance"""""""" mechanism, 2) Creation of a new K-12 Clinical Research Scholars Program offering Masters and PhD level degrees to complement the current Clinical Scholars Program, 3) Infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of Good Clinical Practice (GCP), including biomedical informatics, biostatistics. bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office, 4) Development of innovative and novel core methodologies related to dendritic cell therapy;vaccine development for HIV, hepatitis C, and malignancies;genetics/genomics;assessing the immune response;and metabolic phenotyping. The Center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology, and novel diagnostic, preventive and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The Center will also be an active member of the National CTSA Consortium, offering the Consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will also eagerly adopt the best practices identified by the Consortium and adhere to the standards set by the Consortium. Methillin resistant S. aureus (MRSA) was first identified in clinical specimen in 1961 - shortly after the introduction of the first beta-lactamase resistant antibiotic - Celbenin - into clinical practice. The key component of this resistance mechanism - the mecA gene - encoding a protein with very low affinity to all beta-lactam antibiotics - is not a native gene for S. aureus but has been acquired on multiple occasions from a """"""""foreign"""""""" source in the form of chromosomal cassettes. MRSA clones have emerged as major causative agents of serious - and often life-threatening - infections in hospitals worldwide and beginning with the late 1990s MRSA also found its way into the community. The most widely spread epidemic clones of MRSA also acquired resistance traits to the great majority of antimicrobial agents and therapeutic options against such multidrug resistant strains have become reduced to less than a handful of agents. The primary motive of this grant proposal is to find novel intervention strategies against MRSA by exploring more closely the mechanism of beta-lactam resistance. Critical clues for such novel strategies were observations made in the two collaborating laboratories. The research program will use a combination of genetic, biochemical and metabolomic approaches and will be divided into four Specific Aims.
Aim 1 will use metabolomic approaches to identify the mechanisms by which a library of auxiliary mutants can reduce resistance level of an MRSA strain.
Aim 2 will compare the very different resistance levels produced by subpopulations of heterogeneously resistant epidemic clones of MRSA.
Aim 3 will use genome sequencing to identify determinants in the genetic background of S. aureus that control the level of resistance to oxacillin.
Aim 4 will use five contemporary isolates of MRSA recovered in Yr 2011 in New York hospital

Public Health Relevance

The Rockefeller University Center for Clinical and Translational Science is dedicated to improving human health by providing the resources and personnel to conduct the highest quality research to improve the prevention, diagnosis, and treatment of human disease. It also is producing novel methods to improve the scientific information obtained from clinical research studies and the way in which the research is performed. We are running out of antibiotics that are effective against MRSA. Based on observations made in the collaborating laboratories, this project could provide testable and novel interventions that could lower the resistance of MRSA to beta-lactam antibiotics and other cell wall inhibitory agents.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Linked Specialized Center Cooperative Agreement (UL1)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Rosenblum, Daniel
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rockefeller University
Other Domestic Higher Education
New York
United States
Zip Code
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Levran, Orna; Peles, Einat; Randesi, Matthew et al. (2018) Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroin. Pharmacogenomics 19:333-341
Rosenberg, Brad R; Freije, Catherine A; Imanaka, Naoko et al. (2018) Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. J Infect Dis 217:650-655
Keller, Andreas; Gerkin, Richard C; Guan, Yuanfang et al. (2017) Predicting human olfactory perception from chemical features of odor molecules. Science 355:820-826
Fuentes-Duculan, Judilyn; Bonifacio, Kathleen M; Suárez-Fariñas, Mayte et al. (2017) Aberrant connective tissue differentiation towards cartilage and bone underlies human keloids in African Americans. Exp Dermatol 26:721-727
Ungar, Benjamin; Garcet, Sandra; Gonzalez, Juana et al. (2017) An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol 137:603-613
Butelman, Eduardo Roque; Bacciardi, Silvia; Maremmani, Angelo Giovanni Icro et al. (2017) Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity? Am J Addict 26:632-639
Duvall, Laura B; Basrur, Nipun S; Molina, Henrik et al. (2017) A Peptide Signaling System that Rapidly Enforces Paternity in the Aedes aegypti Mosquito. Curr Biol 27:3734-3742.e5
Fisher, Ffolliott M; Kim, MiSung; Doridot, Ludivine et al. (2017) A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab 6:14-21
Ungar, Benjamin; Correa da Rosa, Joel; Shemer, Avner et al. (2017) Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. Exp Dermatol 26:272-275

Showing the most recent 10 out of 342 publications